Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies
Open Access
Abstract
Objective To establish the prevalence of long-term and serious harms of medical cannabis for chronic pain. Design Systematic review and meta-analysis. Data sources MEDLINE, EMBASE, PsycINFO and CENTRAL from inception to 1 April 2020. Study selection Non-randomised studies reporting on harms of medical cannabis or cannabinoids in adults or children living with chronic pain with ≥4 weeks of follow-up. Data extraction and synthesis A parallel guideline panel provided input on the design and interpretation of the systematic review, including selection of adverse events for consideration. Two reviewers, working independently and in duplicate, screened the search results, extracted data and assessed risk of bias. We used random-effects models for all meta-analyses and the Grades of Recommendations, Assessment, Development and Evaluation approach to evaluate the certainty of evidence. Results We identified 39 eligible studies that enrolled 12 143 adult patients with chronic pain. Very low certainty evidence suggests that adverse events are common (prevalence: 26.0%; 95% CI 13.2% to 41.2%) among users of medical cannabis for chronic pain, particularly any psychiatric adverse events (prevalence: 13.5%; 95% CI 2.6% to 30.6%). Very low certainty evidence, however, indicates serious adverse events, adverse events leading to discontinuation, cognitive adverse events, accidents and injuries, and dependence and withdrawal syndrome are less common and each typically occur in fewer than 1 in 20 patients. We compared studies with Conclusions There is very low certainty evidence that adverse events are common among people living with chronic pain who use medical cannabis or cannabinoids, but that few patients experience serious adverse events.Keywords
All Related Versions
This publication has 85 references indexed in Scilit:
- Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of LifePLOS ONE, 2011
- An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral NeuropathyPain Practice, 2010
- Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter SurveyAnesthesiology Research and Practice, 2009
- Undue reliance on I 2 in assessing heterogeneity may misleadBMC Medical Research Methodology, 2008
- Adverse effects of medical cannabinoids: a systematic reviewCanadian Medical Association Journal, 2008
- Simpson's paradox visualized: The example of the Rosiglitazone meta-analysisBMC Medical Research Methodology, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access RegulationsJournal of Pain and Symptom Management, 2006
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Transformations Related to the Angular and the Square RootThe Annals of Mathematical Statistics, 1950